{"id":529623,"date":"2021-08-19T07:03:27","date_gmt":"2021-08-19T11:03:27","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/larimar-therapeutics-announces-upcoming-oral-presentation-at-the-world-orphan-drug-congress\/"},"modified":"2021-08-19T07:03:27","modified_gmt":"2021-08-19T11:03:27","slug":"larimar-therapeutics-announces-upcoming-oral-presentation-at-the-world-orphan-drug-congress","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/larimar-therapeutics-announces-upcoming-oral-presentation-at-the-world-orphan-drug-congress\/","title":{"rendered":"Larimar Therapeutics Announces Upcoming Oral Presentation at the World Orphan Drug Congress"},"content":{"rendered":"
\n

BALA CYNWYD, Pa., Aug. 19, 2021 (GLOBE NEWSWIRE) — Larimar Therapeutics, Inc. (\u201cLarimar\u201d) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare diseases,\u00a0today announced that David Bettoun, PhD, Vice President Discovery & Non-Clinical R&D of Larimar, will be giving an oral presentation at the World Orphan Drug Congress USA 2021<\/a>, taking place on August 25-27 at the Gaylord National Resort & Convention Center in Oxon Hill, Maryland. Details on the presentation, which will feature preclinical in vitro<\/em> data on Larimar\u2019s proprietary protein replacement therapy platform, can be found below.<\/p>\n\n\n\n\n
\n Presentation Title<\/strong>:<\/td>\nExpanding Therapeutic Possibilities for Rare Diseases: Use of\u00a0Cell Penetrating Peptide (CPP) Technology for Protein Replacement<\/td>\n<\/tr>\n
\n Date:<\/strong>\n <\/td>\nAugust 27, 2021<\/td>\n<\/tr>\n
\n Time:<\/strong>\n <\/td>\n11:35 AM ET<\/td>\n<\/tr>\n<\/table>\n

\n About Larimar Therapeutics<\/strong>
\n
Larimar Therapeutics, Inc.\u00a0(Nasdaq: LRMR) is a clinical-stage biotechnology company focused on developing treatments for complex rare diseases. Larimar\u2019s lead compound, CTI-1601, is currently being evaluated in a Phase 1 clinical program in the\u00a0U.S.\u00a0as a potential treatment for Friedreich’s ataxia.\u00a0Larimar\u00a0also plans to use its intracellular delivery platform to design other fusion proteins to target additional rare diseases characterized by deficiencies in intracellular bioactive compounds. For more information, please visit:\u00a0https:\/\/larimartx.com<\/a>.<\/p>\n

\n Forward-Looking Statements<\/strong>
\n
This press release contains forward-looking statements that are based on Larimar\u2019s management\u2019s beliefs and assumptions and on information currently available to management. All statements contained in this release other than statements of historical fact are forward-looking statements, including but not limited to statements regarding Larimar\u2019s expectations regarding its ability to resolve the clinical hold imposed by the FDA related to CTI-1601, Larimar\u2019s ability to develop and commercialize CTI-1601 and other planned product candidates, Larimar\u2019s planned research and development efforts, and other matters regarding Larimar\u2019s business strategies, use of capital, results of operations and financial position, and plans and objectives for future operations.<\/p>\n

In some cases, you can identify forward-looking statements by the words \u201cmay,\u201d \u201cwill,\u201d \u201ccould,\u201d \u201cwould,\u201d \u201cshould,\u201d \u201cexpect,\u201d \u201cintend,\u201d \u201cplan,\u201d \u201canticipate,\u201d \u201cbelieve,\u201d \u201cestimate,\u201d \u201cpredict,\u201d \u201cproject,\u201d \u201cpotential,\u201d \u201ccontinue,\u201d \u201congoing\u201d or the negative of these terms or other comparable terminology, although not all forward-looking statements contain these words. These statements involve risks, uncertainties and other factors that may cause actual results, performance, or achievements to be materially different from the information expressed or implied by these forward-looking statements. These risks, uncertainties and other factors include, among others, Larimar\u2019s ability to successfully engage with the FDA and satisfactorily respond to requests from the FDA for further information and data regarding CTI-1601, the timing and outcome of Larimar\u2019s planned interactions with the FDA concerning the clinical hold on CTI-1601, the success, cost and timing of Larimar\u2019s product development activities, nonclinical studies and clinical trials, including CTI-1601 clinical milestones; that clinical trial results may differ from final clinical trial results, that earlier non-clinical and clinical data and testing of CTI-1601 may not be predictive of the results or success of clinical trials, and assessments; the ongoing impact of the COVID-19 pandemic on Larimar\u2019s future clinical trials, manufacturing, regulatory and nonclinical study timelines, ability to raise additional capital and general economic conditions; Larimar\u2019s ability to optimize and scale CTI-1601\u2019s manufacturing process; Larimar\u2019s ability to obtain regulatory approval for CTI-1601 and future product candidates; Larimar\u2019s ability to develop sales and marketing capabilities, whether alone or with potential future collaborators, and to successfully commercialize any approved product candidates; Larimar\u2019s ability to raise the necessary capital to conduct its product development activities; and other risks described in the filings made by\u00a0Larimar\u00a0with the\u00a0Securities and Exchange Commission\u00a0(SEC), including but not limited to Larimar\u2019s periodic reports, including the annual report on Form 10-K, quarterly reports on Form 10-Q and current reports on Form 8-K, filed with or furnished to the\u00a0SEC\u00a0and available at\u00a0www.sec.gov<\/a>. These forward-looking statements are based on a combination of facts and factors currently known by\u00a0Larimar\u00a0and its projections of the future, about which it cannot be certain. As a result, the forward-looking statements may not prove to be accurate. The forward-looking statements in this press release represent views as of the date hereof.\u00a0Larimar\u00a0undertakes no obligation to update any forward-looking statements for any reason, except as required by law.<\/p>\n\n\n\n\n\n\n
\n Investor Contact:<\/strong>\n <\/td>\n\n Company Contact:<\/strong>\n <\/td>\n<\/tr>\n
Joyce Allaire<\/td>\nMichael Celano<\/td>\n<\/tr>\n
LifeSci Advisors<\/td>\nChief Financial Officer<\/td>\n<\/tr>\n
\n jallaire@lifesciadvisors.com<\/a>\n <\/td>\n\n mcelano@larimartx.com<\/a>\n <\/td>\n<\/tr>\n
(212) 915-2569<\/td>\n(484) 414-2715<\/td>\n<\/tr>\n<\/table>\n

\u00a0<\/p>\n


\n
\n \n <\/div>\n

<\/div>\n","protected":false},"excerpt":{"rendered":"

BALA CYNWYD, Pa., Aug. 19, 2021 (GLOBE NEWSWIRE) — Larimar Therapeutics, Inc. (\u201cLarimar\u201d) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare diseases,\u00a0today announced that David Bettoun, PhD, Vice President Discovery & Non-Clinical R&D of Larimar, will be giving an oral presentation at the World Orphan Drug Congress USA 2021, taking place on August 25-27 at the Gaylord National Resort & Convention Center in Oxon Hill, Maryland. Details on the presentation, which will feature preclinical in vitro data on Larimar\u2019s proprietary protein replacement therapy platform, can be found below. Presentation Title: Expanding Therapeutic Possibilities for Rare Diseases: Use of\u00a0Cell Penetrating Peptide (CPP) Technology for Protein Replacement Date: August 27, 2021 Time: 11:35 AM ET About Larimar … <\/p>\n

Continue reading “Larimar Therapeutics Announces Upcoming Oral Presentation at the World Orphan Drug Congress”<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-529623","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"\nLarimar Therapeutics Announces Upcoming Oral Presentation at the World Orphan Drug Congress - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/larimar-therapeutics-announces-upcoming-oral-presentation-at-the-world-orphan-drug-congress\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Larimar Therapeutics Announces Upcoming Oral Presentation at the World Orphan Drug Congress - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"BALA CYNWYD, Pa., Aug. 19, 2021 (GLOBE NEWSWIRE) — Larimar Therapeutics, Inc. (\u201cLarimar\u201d) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare diseases,\u00a0today announced that David Bettoun, PhD, Vice President Discovery & Non-Clinical R&D of Larimar, will be giving an oral presentation at the World Orphan Drug Congress USA 2021, taking place on August 25-27 at the Gaylord National Resort & Convention Center in Oxon Hill, Maryland. Details on the presentation, which will feature preclinical in vitro data on Larimar\u2019s proprietary protein replacement therapy platform, can be found below. Presentation Title: Expanding Therapeutic Possibilities for Rare Diseases: Use of\u00a0Cell Penetrating Peptide (CPP) Technology for Protein Replacement Date: August 27, 2021 Time: 11:35 AM ET About Larimar … Continue reading "Larimar Therapeutics Announces Upcoming Oral Presentation at the World Orphan Drug Congress"\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/larimar-therapeutics-announces-upcoming-oral-presentation-at-the-world-orphan-drug-congress\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2021-08-19T11:03:27+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODMxMTUxMiM0MzY1MDk1IzUwMDA3Nzg4OQ==\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/larimar-therapeutics-announces-upcoming-oral-presentation-at-the-world-orphan-drug-congress\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/larimar-therapeutics-announces-upcoming-oral-presentation-at-the-world-orphan-drug-congress\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Larimar Therapeutics Announces Upcoming Oral Presentation at the World Orphan Drug Congress\",\"datePublished\":\"2021-08-19T11:03:27+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/larimar-therapeutics-announces-upcoming-oral-presentation-at-the-world-orphan-drug-congress\\\/\"},\"wordCount\":739,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/larimar-therapeutics-announces-upcoming-oral-presentation-at-the-world-orphan-drug-congress\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODMxMTUxMiM0MzY1MDk1IzUwMDA3Nzg4OQ==\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/larimar-therapeutics-announces-upcoming-oral-presentation-at-the-world-orphan-drug-congress\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/larimar-therapeutics-announces-upcoming-oral-presentation-at-the-world-orphan-drug-congress\\\/\",\"name\":\"Larimar Therapeutics Announces Upcoming Oral Presentation at the World Orphan Drug Congress - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/larimar-therapeutics-announces-upcoming-oral-presentation-at-the-world-orphan-drug-congress\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/larimar-therapeutics-announces-upcoming-oral-presentation-at-the-world-orphan-drug-congress\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODMxMTUxMiM0MzY1MDk1IzUwMDA3Nzg4OQ==\",\"datePublished\":\"2021-08-19T11:03:27+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/larimar-therapeutics-announces-upcoming-oral-presentation-at-the-world-orphan-drug-congress\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/larimar-therapeutics-announces-upcoming-oral-presentation-at-the-world-orphan-drug-congress\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/larimar-therapeutics-announces-upcoming-oral-presentation-at-the-world-orphan-drug-congress\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODMxMTUxMiM0MzY1MDk1IzUwMDA3Nzg4OQ==\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODMxMTUxMiM0MzY1MDk1IzUwMDA3Nzg4OQ==\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/larimar-therapeutics-announces-upcoming-oral-presentation-at-the-world-orphan-drug-congress\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Larimar Therapeutics Announces Upcoming Oral Presentation at the World Orphan Drug Congress\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Larimar Therapeutics Announces Upcoming Oral Presentation at the World Orphan Drug Congress - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/larimar-therapeutics-announces-upcoming-oral-presentation-at-the-world-orphan-drug-congress\/","og_locale":"en_US","og_type":"article","og_title":"Larimar Therapeutics Announces Upcoming Oral Presentation at the World Orphan Drug Congress - Market Newsdesk","og_description":"BALA CYNWYD, Pa., Aug. 19, 2021 (GLOBE NEWSWIRE) — Larimar Therapeutics, Inc. (\u201cLarimar\u201d) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare diseases,\u00a0today announced that David Bettoun, PhD, Vice President Discovery & Non-Clinical R&D of Larimar, will be giving an oral presentation at the World Orphan Drug Congress USA 2021, taking place on August 25-27 at the Gaylord National Resort & Convention Center in Oxon Hill, Maryland. Details on the presentation, which will feature preclinical in vitro data on Larimar\u2019s proprietary protein replacement therapy platform, can be found below. Presentation Title: Expanding Therapeutic Possibilities for Rare Diseases: Use of\u00a0Cell Penetrating Peptide (CPP) Technology for Protein Replacement Date: August 27, 2021 Time: 11:35 AM ET About Larimar … Continue reading \"Larimar Therapeutics Announces Upcoming Oral Presentation at the World Orphan Drug Congress\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/larimar-therapeutics-announces-upcoming-oral-presentation-at-the-world-orphan-drug-congress\/","og_site_name":"Market Newsdesk","article_published_time":"2021-08-19T11:03:27+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODMxMTUxMiM0MzY1MDk1IzUwMDA3Nzg4OQ==","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/larimar-therapeutics-announces-upcoming-oral-presentation-at-the-world-orphan-drug-congress\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/larimar-therapeutics-announces-upcoming-oral-presentation-at-the-world-orphan-drug-congress\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Larimar Therapeutics Announces Upcoming Oral Presentation at the World Orphan Drug Congress","datePublished":"2021-08-19T11:03:27+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/larimar-therapeutics-announces-upcoming-oral-presentation-at-the-world-orphan-drug-congress\/"},"wordCount":739,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/larimar-therapeutics-announces-upcoming-oral-presentation-at-the-world-orphan-drug-congress\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODMxMTUxMiM0MzY1MDk1IzUwMDA3Nzg4OQ==","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/larimar-therapeutics-announces-upcoming-oral-presentation-at-the-world-orphan-drug-congress\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/larimar-therapeutics-announces-upcoming-oral-presentation-at-the-world-orphan-drug-congress\/","name":"Larimar Therapeutics Announces Upcoming Oral Presentation at the World Orphan Drug Congress - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/larimar-therapeutics-announces-upcoming-oral-presentation-at-the-world-orphan-drug-congress\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/larimar-therapeutics-announces-upcoming-oral-presentation-at-the-world-orphan-drug-congress\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODMxMTUxMiM0MzY1MDk1IzUwMDA3Nzg4OQ==","datePublished":"2021-08-19T11:03:27+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/larimar-therapeutics-announces-upcoming-oral-presentation-at-the-world-orphan-drug-congress\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/larimar-therapeutics-announces-upcoming-oral-presentation-at-the-world-orphan-drug-congress\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/larimar-therapeutics-announces-upcoming-oral-presentation-at-the-world-orphan-drug-congress\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODMxMTUxMiM0MzY1MDk1IzUwMDA3Nzg4OQ==","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODMxMTUxMiM0MzY1MDk1IzUwMDA3Nzg4OQ=="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/larimar-therapeutics-announces-upcoming-oral-presentation-at-the-world-orphan-drug-congress\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Larimar Therapeutics Announces Upcoming Oral Presentation at the World Orphan Drug Congress"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/529623","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=529623"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/529623\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=529623"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=529623"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=529623"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}